English

DICE THERAPEUTICS, INC.

EDGAR

DICE Quarterly report (10-Q) · filed 2023-08-08

10 filing records in this dataset, filed from 2021-08-25 to 2023-08-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2021 Q4 · USD

Exact inputs and evidence

Revenue: 1125000 USD Source
Revenue: 1125000 USD Source

Operating cash flow

-14.4 million USD

2021 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -39292000 USD Source
Operating Cash Flow: -24880000 USD Source

Free cash flow

-14.6 million USD

2021 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -39292000 USD Source
Operating Cash Flow: -24880000 USD Source
Capital Expenditure: 718000 USD Source
Capital Expenditure: 522000 USD Source

Cash and cash equivalents: 73.5 million USD 2023-06-30 Source
Exact value

73464000 USD
Long-term debt including current maturities: 2.4 million USD 2021-12-31 Source
Exact value

2396000 USD
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-104 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Net income: -20550000 USD · 2022-07-01 – 2022-09-30 Source
Net income: -83887000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -60663000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -25646000 USD · 2023-01-01 – 2023-03-31 Source
Net income: -34816000 USD · 2023-04-01 – 2023-06-30 Source

Operating cash flow

-84.2 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Operating cash flow: -46430000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -31106000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -64322000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -46430000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -22436000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -51012000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -22436000 USD · 2023-01-01 – 2023-03-31 Source

Capital expenditure

2.99 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Capital expenditure: 1800000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 1276000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 2237000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 1800000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 202000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 2031000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 202000 USD · 2023-01-01 – 2023-03-31 Source

Free cash flow

-87.2 million USD

2022-07-01 – 2023-06-30

Exact inputs and evidence

Operating cash flow: -46430000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -31106000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -64322000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -46430000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -22436000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -51012000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -22436000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 1800000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 1276000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 2237000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 1800000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 202000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 2031000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 202000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-08-08.

Financial data available through: 2021-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2021-12-31
Operating income: 2 of 11 periods available· newest 2021-12-31
Net income: 2 of 11 periods available· newest 2021-12-31
Operating cash flow: 2 of 11 periods available· newest 2021-12-31
Capital expenditure: 2 of 11 periods available· newest 2021-12-31
Total assets: 2 of 11 periods available· newest 2021-12-31
Total liabilities: 2 of 11 periods available· newest 2021-12-31
Current assets: 2 of 11 periods available· newest 2021-12-31
Current liabilities: 2 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2021-12-31
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+30.4%

Prior period

USD 863,000

2020-01-01 – 2020-12-31
Current period

USD 1.13 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

1125000 − 863000 = 262000 USD

863000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
1125000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · DICE THERAPEUTICS, INC. · 2021-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Year-over-year change in Revenue: 262000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1125000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#1678883 Filing: 000095017023008119 Input fundies:Revenue: 863000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#1574293 Filing: 000156459022011972
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 25.22 million

Prior period

−USD 23.74 million

2020-01-01 – 2020-12-31
Current period

−USD 48.96 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-48959000 − -23739000 = -25220000 USD

-23739000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-48959000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · DICE THERAPEUTICS, INC. · 2021-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Year-over-year change in Net income: -25220000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -48959000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#2185922 Filing: 000095017023008119 Input fundies:NetIncome: -23739000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#2028253 Filing: 000156459022011972
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 18.61 million

Prior period

−USD 20.68 million

2020-01-01 – 2020-12-31
Current period

−USD 39.29 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-39292000 − -20679000 = -18613000 USD

-20679000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-39292000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · DICE THERAPEUTICS, INC. · 2021-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Year-over-year change in Operating cash flow: -18613000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -39292000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#2262061 Filing: 000095017023008119 Input fundies:OperatingCashFlow: -20679000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#2082888 Filing: 000156459022011972
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+385.1%

Prior period

USD 148,000

2020-01-01 – 2020-12-31
Current period

USD 718,000

2021-01-01 – 2021-12-31

Exact inputs and evidence

718000 − 148000 = 570000 USD

148000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
718000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · DICE THERAPEUTICS, INC. · 2021-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Year-over-year change in Capital expenditure: 570000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 718000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#2270024 Filing: 000095017023008119 Input fundies:CapitalExpenditure: 148000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#2090521 Filing: 000156459022011972
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 1.13 million 100% of revenue
Operating costs Derived USD 48.73 million 4,331% of revenue
Operating income −USD 47.6 million −4,231% of revenue
Tax, interest and other Derived USD 1.36 million 121% of revenue
Net income −USD 48.96 million −4,352% of revenue

Cash

Operating cash flow −USD 39.29 million −3,493% of revenue
Capital expenditure USD 718,000 64% of revenue
Free cash flow Derived −USD 40.01 million −3,556% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 2,849% of revenue.
2021 Operating loss: operating costs were 4,331% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	863000	24584000 Derived	-23721000	18000 Derived	-23739000	-20827000 Derived	Source 2020-01-01 – 2020-12-31: 863000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -23721000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -23739000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -20679000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 148000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1125000	48728000 Derived	-47603000	1356000 Derived	-48959000	-40010000 Derived	Source 2021-01-01 – 2021-12-31: 1125000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -47603000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -48959000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -39292000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 718000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.1M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	863000	Revenue: 863000 Open source
20212021-12-31	Revenue	1125000	Revenue: 1125000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

30.4% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 863000 Open source
20212021-12-31	Year over year	30.4%	Revenue: 1125000 Open source Revenue: 863000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,231.4% 2021

Net margin -4,351.9% 2021

Free cash flow margin -3,556.4% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-2,748.7%	Operating Income: -23721000 Open source Revenue: 863000 Open source
20212021-12-31	Operating margin	-4,231.4%	Operating Income: -47603000 Open source Revenue: 1125000 Open source
20202020-12-31	Net margin	-2,750.8%	Net Income: -23739000 Open source Revenue: 863000 Open source
20212021-12-31	Net margin	-4,351.9%	Net Income: -48959000 Open source Revenue: 1125000 Open source
20202020-12-31	Free cash flow margin	-2,413.3%	Revenue: 863000 Open source Operating Cash Flow: -20679000 Open source Capital Expenditure: 148000 Open source
20212021-12-31	Free cash flow margin	-3,556.4%	Revenue: 1125000 Open source Operating Cash Flow: -39292000 Open source Capital Expenditure: 718000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -39.3M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-20679000	Operating Cash Flow: -20679000 Open source
20212021-12-31	Operating cash flow	-39292000	Operating Cash Flow: -39292000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -40M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-20827000	Operating Cash Flow: -20679000 Open source Capital Expenditure: 148000 Open source
20212021-12-31	Free cash flow	-40010000	Operating Cash Flow: -39292000 Open source Capital Expenditure: 718000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

3.9% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	15.1%	Total Liabilities: 9632000 Open source Total Assets: 63861000 Open source
20212021-12-31	Liabilities / assets	3.9%	Total Liabilities: 12805000 Open source Total Assets: 325754000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

29.77× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	6.68×	Current Assets: 62051000 Open source Current Liabilities: 9290000 Open source
20212021-12-31	Current assets / current liabilities	29.77×	Current Assets: 323911000 Open source Current Liabilities: 10881000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 23.74 million Exact value Exact value: -23739000 USD 2020-01-01 – 2020-12-31: -23739000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICE THERAPEUTICS, INC. · 2020-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Net Income: -23739000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23739000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#2028253 Filing: 000156459022011972 The citation records this snapshot. The page link may show a newer release later.	−USD 20.68 million Exact value Exact value: -20679000 USD 2020-01-01 – 2020-12-31: -20679000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICE THERAPEUTICS, INC. · 2020-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Operating Cash Flow: -20679000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20679000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#2082888 Filing: 000156459022011972 The citation records this snapshot. The page link may show a newer release later.	USD 148,000 Exact value Exact value: 148000 USD 2020-01-01 – 2020-12-31: 148000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICE THERAPEUTICS, INC. · 2020-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Capital Expenditure: 148000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 148000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#2090521 Filing: 000156459022011972 The citation records this snapshot. The page link may show a newer release later.	−USD 20.83 million Calculation and evidence -20679000 − 148000 USD Exact free cash flow: -20827000 USD 2020-01-01 – 2020-12-31: -20679000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 148000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICE THERAPEUTICS, INC. · 2020-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Free cash flow: -20827000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20679000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#2082888 Filing: 000156459022011972 Input fundies:CapitalExpenditure: 148000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000156459022011972/dice-10k_20211231.htm#2090521 Filing: 000156459022011972 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 48.96 million Exact value Exact value: -48959000 USD 2021-01-01 – 2021-12-31: -48959000 USD Inspect Net Income Open source Share or cite Citation for Net Income · DICE THERAPEUTICS, INC. · 2021-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Net Income: -48959000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48959000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#2185922 Filing: 000095017023008119 The citation records this snapshot. The page link may show a newer release later.	−USD 39.29 million Exact value Exact value: -39292000 USD 2021-01-01 – 2021-12-31: -39292000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · DICE THERAPEUTICS, INC. · 2021-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Operating Cash Flow: -39292000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39292000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#2262061 Filing: 000095017023008119 The citation records this snapshot. The page link may show a newer release later.	USD 718,000 Exact value Exact value: 718000 USD 2021-01-01 – 2021-12-31: 718000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · DICE THERAPEUTICS, INC. · 2021-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Capital Expenditure: 718000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 718000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#2270024 Filing: 000095017023008119 The citation records this snapshot. The page link may show a newer release later.	−USD 40.01 million Calculation and evidence -39292000 − 718000 USD Exact free cash flow: -40010000 USD 2021-01-01 – 2021-12-31: -39292000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 718000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · DICE THERAPEUTICS, INC. · 2021-12-31 DICE THERAPEUTICS, INC. (edgar:1645569) Free cash flow: -40010000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:42:31Z Snapshot: 2fbca020a3b1a3920ec51a910fa98a0db8635d0ebbb06756403649f6e697ad49 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1645569?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39292000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#2262061 Filing: 000095017023008119 Input fundies:CapitalExpenditure: 718000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm#2270024 Filing: 000095017023008119 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

10 filings · 562 latest values · 562 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001645569, 1645569, DICE, edgar:1645569

Also known as DICE THERAPEUTICS, INC., DICE Therapeutics, Inc., DiCE MOLECULES HOLDINGS, LLC, DiCE Molecules Holdings, LLC

DICE THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation